Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care. Circulating tumor DNA, also referred to as ctDNA, are small pieces of DNA that are ...

We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...

A study led by scientists at NYU Langone Health and its Perlmutter Cancer Center has shown that monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer ...

or on the link below. The growing sophistication of tumor molecular profiling has helped to slowly transition oncologic care toward a more personalized approach in different tumor types, including in ...

Serum tumor markers (STMs), including alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG), are currently used in management of patients with germ cell tumors (GCTs). STMs in a substantial ...

Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ctDNA. Among patients with metastatic renal cell carcinoma (mRCC), serial ...

Circulating tumour DNA (ctDNA) monitoring identified patients with muscle-invasive bladder cancer who showed significantly longer disease-free survival and overall survival when treated with adjuvant ...

In A Nutshell Johns Hopkins researchers developed a blood test that catches 81% of stage IA lung cancers (the earliest, most ...

The researchers found that within 4 months after blood collection, all 8 participants who scored positively with a multicancer early detection (MCED) test were diagnosed with cancer. HealthDay News — ...

Colorectal cancer (CRC) is a major public health issue, with over 43,000 new cases and nearly 17,700 deaths annually in France. The overall survival rate is currently 63%. It is much higher for early ...